Functional analysis ofRYR1variants linked to malignant hyperthermia
Open Access
- 26 February 2016
- journal article
- research article
- Published by Taylor & Francis in Temperature
- Vol. 3 (2) , 328-339
Abstract
Malignant hyperthermia manifests as a rapid and sustained rise in temperature in response to pharmacological triggering agents, e.g. inhalational anesthetics and the muscle relaxant suxamethonium. Other clinical signs include an increase in end-tidal CO2, increased O2 consumption, as well as tachycardia, and if untreated a malignant hyperthermia episode can result in death. The metabolic changes are caused by dysregulation of skeletal muscle Ca2+ homeostasis, resulting from a defective ryanodine receptor Ca2+ channel, which resides in the sarcoplasmic reticulum and controls the flux of Ca2+ ions from intracellular stores to the cytoplasm. Most genetic variants associated with susceptibility to malignant hyperthermia occur in the RYR1 gene encoding the ryanodine receptor type 1. While malignant hyperthermia susceptibility can be diagnosed by in vitro contracture testing of skeletal muscle biopsy tissue, it is advantageous to use DNA testing. Currently only 35 of over 400 potential variants in RYR1 have been classed as functionally causative of malignant hyperthermia and thus can be used for DNA diagnostic tests. Here we describe functional analysis of 2 RYR1 variants (c. 7042_7044delCAG, p.ΔGlu2348 and c.641C>T, p.Thr214Met) that occur in the same malignant hyperthermia susceptible family. The p.Glu2348 deletion, causes hypersensitivity to ryanodine receptor agonists using in vitro analysis of cloned human RYR1 cDNA expressed in HEK293T cells, while the Thr214Met substitution, does not appear to significantly alter sensitivity to agonist in the same system. We suggest that the c. 7042_7044delCAG, p.ΔGlu2348 RYR1 variant could be added to the list of diagnostic mutations for susceptibility to malignant hyperthermia.Keywords
This publication has 39 references indexed in Scilit:
- Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca 2+ channel and the type 1 ryanodine receptorProceedings of the National Academy of Sciences, 2012
- Malignant hyperthermia: pharmacology of triggeringBritish Journal of Anaesthesia, 2011
- Clinical utility gene card for: malignant hyperthermiaEuropean Journal of Human Genetics, 2011
- Functional Properties of RYR1 Mutations Identified in Swedish Patients with Malignant Hyperthermia and Central Core DiseaseAnesthesia & Analgesia, 2010
- Functional Studies of RYR1 Mutations in the Skeletal Muscle Ryanodine Receptor Using Human RYR1 Complementary DNAAnesthesiology, 2010
- Postulated role of interdomain interaction between regions 1 and 2 within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermiaBiochemical Journal, 2007
- Mutations inRYR1in malignant hyperthermia and central core diseaseHuman Mutation, 2006
- Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing?European Journal of Human Genetics, 2003
- RyR1/SERCA1 cross-talk regulation of calcium transport in heavy sarcoplasmic reticulum vesiclesCanadian Journal of Physiology and Pharmacology, 2003
- Malignant hyperthermiaEuropean Journal of Anaesthesiology, 2001